Abstract
Background: Constipation is a significant symptom of Parkinson's disease (PD). Glial-derived neurotrophic factor (GDNF) is important for the morphogenesis of the enteric nervous system and plays a critical role in the preservation of mucosal integrity under enteric glia surveillance. The aim of this work was to evaluate the serum levels of GDNF in patients with PD with and without constipation.Methods: This work included 128 patients with PD. The patients were classified into three groups: those with PD but no constipation (nCons-PD) (n = 49), those with prodromal stage constipation (Cons-Pro-PD) (n = 48), and those with clinical stage constipation (Cons-Clinic-PD) (n = 31). The association between serum GDNF concentration and constipation was explored using logical regression.Results: The nCons-PD group's mean GDNF levels were 528.44 pg/ml, which was higher than the Cons-Pro-PD group's 360.72 pg/ml and the Cons-Clinic-PD group's 331.36 pg/ml. The results of binary logistic regression indicated that GDNF was a protective factor in the prevention of constipation. Cons-Clinic-PD group had a higher score of MDS-UPDRS-II, MDS-UPDRS-III, MDS-UPDRS-IV, and a higher H-Y staging as compared with nCons-PD group. Relative to the nCons-PD group, Cons-Clinic-PD had higher NMSS scores, lower MoCA and PDSS scores, and were more likely to have RBD.Conclusions: GDNF serum levels are lower in patients with PD who are constipated. A low GDNF level is a potential risk factor for constipation in patients with PD.
Highlights
Parkinson’s disease (PD) is the second most prevalent neurodegenerative condition, affecting 2–3% of the population over the age of 65 (1) worldwide and 1.7% of the population over the age of 65 years in China (2), and it is an incurable multisystem condition that causes severe morbidity and healthcare burden
Multiple studies have explored the association between PD and intestinal nervous system, intestinal glial cells, and constipation, but it is perplexing whether Glial-derived neurotrophic factor (GDNF) serum level is a risk factor in patients with PD with constipation.Here, we report an association of GDNF serum level and constipation in patients with PD using logistic regression model
This study included 128 patients with PD who were classified into three groups: those who did not have constipation (n = 49), those who had prodromal constipation (Cons-Pro-PD) (n = 48), and those who did have clinical constipation (ConsClinic-PD) (n = 31) (Table 1)
Summary
Parkinson’s disease (PD) is the second most prevalent neurodegenerative condition, affecting 2–3% of the population over the age of 65 (1) worldwide and 1.7% of the population over the age of 65 years in China (2), and it is an incurable multisystem condition that causes severe morbidity and healthcare burden. GI dysfunctions are the most common NMS of PD, affecting ∼65% (6) of the patients and having a significant negative effect on the QoL. It can occur up to 15 years before motor symptoms and is included in the research criteria for prodromal PD diagnostics as one of the risk factors for potential PD development (10). The correlation between constipation in patients with PD and glial cell line derived neurotrophic factor is elusive. Multiple studies have explored the association between PD and intestinal nervous system, intestinal glial cells, and constipation, but it is perplexing whether GDNF serum level is a risk factor in patients with PD with constipation.Here, we report an association of GDNF serum level and constipation in patients with PD using logistic regression model. The aim of this work was to evaluate the serum levels of GDNF in patients with PD with and without constipation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
